SPOTLIGHT: NIH starts Tykerb vs. Herceptin bout

It's a head-to-head matchup. The National Institutes of Health has launched an 8,000-patient trial pitting GlaxoSmithKline's Tykerb against Genentech's Herceptin in aggressive breast cancer. Meanwhile, GSK is poised to launch its med in the U.K. as Tyverb. Report | Report